Division of Infectious Diseases, Wayne State University, Detroit, Michigan, USA.
Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7. doi: 10.1128/AAC.05913-11. Epub 2012 Jan 30.
Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).
厄他培南对产超广谱β-内酰胺酶（ESBL）的肠杆菌科细菌具有活性，但对铜绿假单胞菌和鲍曼不动杆菌无活性。由于缺乏厄他培南治疗产 ESBL 血流感染（BSI）的治疗数据，因此常选择第 2 代碳青霉烯类药物（如亚胺培南或美罗培南）治疗产 ESBL 的肠杆菌科细菌，尽管它们的抗假单胞菌活性是不必要的。2005 年至 2010 年，分析了 261 例产 ESBL BSI 患者。接受厄他培南和第 2 代碳青霉烯类药物治疗的患者的结局相当（死亡率分别为 6%和 18%；P=0.18）。
